onabotulinumtoxinA与骶神经调节治疗难治性急迫性尿失禁后治疗反应的纵向波动
本研究将一项随机试验数据拟合马尔可夫模型,比较200 U onabotulinumtoxinA与骶神经调节治疗急迫性尿失禁6个月内成功/失败状态转换。357名参与者中,onabotulinumtoxinA组较骶神经调节组持续客观成功比例更高(61% vs 51%),30天从客观和主观成功转为失败的概率更低(10% vs 14%,比值0.75;14% vs 21%,比值0.70),而失败转为成功的概率两组无差异。
要点
- onabotulinumtoxinA组6个月内持续客观成功比例61%,骶神经调节组51%。
- onabotulinumtoxinA组30天客观成功转失败概率10%,低于骶神经调节组的14%(比值0.75)。
- 两种治疗失败后30天内恢复成功的概率约为20%-40%。
核心结论
- 治疗6个月内,约五分之二女性症状出现波动。
- 在初始6个月内,接受onabotulinumtoxinA的女性30天内从成功转为失败的概率低于骶神经调节。
- 两种治疗失败后30天内恢复主观和客观成功的概率约为20%-40%。
研究设计与样本
- 将一项随机试验的数据拟合马尔可夫模型,比较200 U onabotulinumtoxinA与骶神经调节治疗6个月内成功/失败状态转换。
- 共357名参与者,基线每日急迫性尿失禁发作中位数4.7次(IQR 3.7-6.0)。
主要发现
- onabotulinumtoxinA组 vs 骶神经调节组6个月内持续客观成功比例为61% vs 51%,持续客观失败比例为3.2% vs 6.1%。
- onabotulinumtoxinA组 vs 骶神经调节组30天客观成功转失败概率为10% vs 14%,比值0.75(95% CI 0.55-0.95)。
- onabotulinumtoxinA组 vs 骶神经调节组30天主观成功转失败概率为14% vs 21%,比值0.70(95% CI 0.51-0.89)。
- onabotulinumtoxinA组 vs 骶神经调节组30天客观失败转成功概率为40% vs 36%,比值1.11(95% CI 0.73-1.50)。
- onabotulinumtoxinA组 vs 骶神经调节组30天主观失败转成功概率为18% vs 17%,比值1.14(95% CI 0.65-1.64)。
关键数值与推荐
- 客观失败定义为急迫性尿失禁发作较基线减少<50%。
- 主观失败定义为患者整体症状控制问卷回答从「强烈不同意」到「中性」。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared fluctuations in treatment response after onabotulinumtoxinA and sacral neuromodulation for urgency incontinence using Markov models. MATERIALS AND METHODS: We fit data from a randomized trial to Markov models to compare transitions of success/failure over 6 months between 200 U onabotulinumtoxinA and sacral neuromodulation. Objective failure was <50% reduction in urgency incontinence episodes from baseline; subjective failure "strongly disagree" to "neutral" to the Patient Global Symptom Control questionnaire. RESULTS: Of the 357 participants (median baseline daily urgency incontinence episodes 4.7 [IQR 3.7-6.0]) 61% vs 51% and 3.2% vs 6.1% reported persistent states of objective success and failure over 6 months after onabotulinumtoxinA vs sacral neuromodulation. Participants receiving onabotulinumtoxinA vs sacral neuromodulation had lower 30-day transition probabilities from objective and subjective success to failure (10% vs 14%, ratio 0.75 [95% CI 0.55-0.95]; 14% vs 21%, ratio 0.70 [95% CI 0.51-0.89]). The 30-day transition probability from objective and subjective failure to success did not differ between onabotulinumtoxinA and sacral neuromodulation (40% vs 36%, ratio 1.11 [95% CI 0.73-1.50]; 18% vs 17%, ratio 1.14 [95% CI 0.65-1.64]). CONCLUSIONS: Over 6 months after treatment, 2 in 5 women's symptoms fluctuate. Within these initial 6 months, women receiving onabotulinumtoxinA transitioned from success to failure over 30 days less often than sacral neuromodulation. For both treatments, there was an almost 20%-40% probability over 30 days that women returned to subjective and objective success after failure. Markov models add important information to longitudinal models on how symptoms fluctuate after urgency incontinence treatment.
引用
- Hendrickson WK, Zhang C, Jelovsek JE, et al. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence. J Urol. 2023. PMID: 37871326. doi:10.1097/JU.0000000000003746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。